On December 16, 2025, Tolmar, Inc., a specialty pharmaceutical company, inaugurated its new Northern Illinois Laboratory at the Rosalind Franklin University (RFU) Innovation and Research Park (IRP) in North Chicago, Illinois. This facility enhances Tolmar’s capacity to develop and commercialize pharmaceutical products and strengthens the university’s commitment to fostering industry innovation.
Founded in 2007, Tolmar is recognized internationally for its expertise in long-acting injectable drug delivery. The company specializes in pharmaceuticals targeting urology, oncology, and endocrinology, with its leading product utilized in the treatment of advanced prostate cancer and available in 89 countries.
Expansion of Development Capabilities
The new laboratory at RFU complements Tolmar’s existing facilities in Colorado, enabling a collaborative approach among researchers, engineers, and operations staff. The Illinois site not only expands the company’s regional presence but also includes executive offices and sales and marketing teams based in Buffalo Grove, Illinois.
Dr. Dave Loffredo, Vice President of Innovation at Tolmar, expressed enthusiasm about the expansion, stating, “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois. After an exhaustive search, we found a great home at Rosalind Franklin’s IRP.” He emphasized the eagerness of Tolmar’s scientists to engage with the vibrant research environment the university offers.
Collaborative Potential at RFU
Dr. Stace Porter, Senior Vice President of Development Operations for Tolmar, highlighted the potential of the new lab, saying, “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores.” The IRP is strategically located within Lake County’s network of global life science companies, providing ample opportunities for growth and innovation.
The RFU Innovation and Research Park spans 100,000 square feet and houses six research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. Dr. Joseph DiMario, Executive Vice President for Research at RFU, welcomed Tolmar to its growing ecosystem. “We look forward to collaborations that can help accelerate new product development,” he stated. “The IRP provides an environment that fosters the kind of intellectual biomedical collisions that drive meaningful innovation.”
As Tolmar continues to expand its footprint in the pharmaceutical landscape, the collaboration with Rosalind Franklin University is poised to enhance research and development capabilities, potentially leading to significant advancements in the treatment of various medical conditions.
For further details about Tolmar, visit www.tolmar.com.
To learn more about Rosalind Franklin University, explore rosalindfranklin.edu.
